Testosterone replacement therapy and the broader hormone optimization industry have grown from a niche endocrine specialty into a mainstream wellness category. Millions of men now pursue these treatments through clinics and telehealth platforms. That has brought real benefit to patients who genuinely suffer from hypogonadism, a condition in which the body does not produce sufficient testosterone and may also affect sperm production. Yet it has also created a legal exposure problem that many clinic owners never anticipated when they opened their doors.
As a clinic owner specialized in hormone therapy and a wellness expert, I have watched this specialty move from a quiet corner of endocrinology into one of the most actively litigated areas of wellness medicine in the country. Attorneys on both sides of the bar are taking notice.
Hormone optimization is booming. So why is it becoming a litigation minefield?
Market research describes the global testosterone replacement therapy market as a segment that has moved from $2 billion toward a projected figure above $5 billion within the next decade. The identified fastest-growing distribution channels for these services are:
- Telehealth platforms
- Retail health clinics
- Wellness centers
All of these are convenience-based delivery models, which matter a great deal from a liability standpoint, because a treatment that once required an in-person relationship with an endocrinologist can now be initiated through an online questionnaire and a lab draw at a local diagnostic center. As access to testosterone therapy has increased, new challenges and legal risks have emerged. These include alleged treatment-related injuries, negligent prescribing, inadequate monitoring, and failures in informed consent. These issues have contributed to increased litigation in this area. A multidistrict litigation involving major pharmaceutical manufacturers consolidated thousands of testosterone product liability claims in federal court beginning in 2014. That litigation wave has largely resolved, even though the underlying pattern it revealed remains.
Real physician voices, twice a week
Free, and one click to unsubscribe.
Patients who experience cardiovascular events or other complications after starting hormone therapy continue to look for someone to hold accountable. Increasingly, that scrutiny is shifting from the drug manufacturer to the clinic and prescriber when adequate screening or follow-up was not provided. Reported cases involving endocrinologists sued for negligent prescribing and failure to obtain informed consent show how one treatment decision can lead to two separate legal claims, each requiring its own evidence and often its own expert testimony. For attorneys evaluating whether a case has merit, and for clinic operators trying to understand where their own exposure sits, this growth pattern is the reason a hormone optimization liability expert attorney relationship has become almost as important as the treating physician relationship itself.
The standard of care that comes before every prescription
Hormone optimization is not a treatment that can be administered safely through a “one size fits all” protocol, and you might even run into trouble. The Endocrine Society’s clinical practice guideline on testosterone therapy lays out a detailed diagnostic and monitoring framework that any clinic offering these services should be following closely. Before treatment even begins, the guideline calls for:
- Confirmed low testosterone levels: The patient’s testosterone deficiency should be established through reliable laboratory testing before treatment begins.
- Baseline hematocrit measurement: A blood test that measures the proportion of red blood cells in the blood and helps identify patients who may face an increased risk of complications from testosterone therapy.
- For men over forty: A baseline PSA (prostate-specific antigen, a protein measured through a blood test that can help identify potential prostate abnormalities) and a digital prostate examination along with PSA testing.
The guideline further identifies a list of conditions under which testosterone therapy should not be started at all:
- Elevated hematocrit
- Untreated severe sleep apnea
- Uncontrolled heart failure
- A recent heart attack or stroke
- Certain prostate findings
Once treatment begins, there is a monitoring obligation. The same guideline calls for:
- Repeat hematocrit testing at three to six months and then annually throughout treatment.
- Pausing therapy if hematocrit rises above a defined safety threshold.
- Investigating for hypoxia or sleep apnea before resuming treatment at a lower dose.
- PSA monitoring for appropriate patients following a similar schedule. A confirmed PSA rise beyond a specified amount within twelve months should prompt a referral to urology and further clinical evaluation.
These suggestions function as the working definition of the standard of care that a testosterone replacement therapy negligence expert will apply when reviewing whether a clinic’s conduct fell short. Informed consent sits alongside individualized treatment planning and laboratory monitoring as the third pillar a clinic must get right. Legal commentary on medical informed consent distinguishes two disclosure standards:
- The physician-centered standard: What a reasonably prudent physician would typically disclose.
- The patient-centered standard: What a reasonable patient would want to know before agreeing to treatment.
In practical terms, this means a clinic must document that the patient understood the fertility risks, the cardiovascular and clotting risks, the polycythemia risk, the prostate-related risks, and the realistic alternatives to hormone therapy before that patient ever received a first injection. Throughout my career, I have observed that cases involving testosterone patients have shown that even when the underlying medical decision to prescribe was defensible, a documented gap in the consent conversation can carry a claim past a motion to dismiss and in front of a jury.
Where malpractice claims actually originate inside a hormone therapy program
Malpractice claims in hormone therapy programs most commonly arise from:
- Inadequate baseline screening: A patient begins therapy without a confirmed diagnosis of low testosterone through appropriately timed lab draws, or without the cardiovascular and prostate workup the guidelines call for.
- Monitoring drift: A clinic performs the correct baseline testing but then fails to bring the patient back on schedule for the three- to six-month and annual follow-up labs, allowing a rising hematocrit or an elevated PSA to go unnoticed until the patient presents with a stroke, a clot, or a late-stage diagnosis.
- Dosing decisions: Made without regard to the patient’s actual lab values, particularly in clinics that rely on standardized dosing protocols not tailored to individual patients’ response and risk profile.
- Documentation gaps around informed consent: The clinic’s own records cannot demonstrate that specific risks were discussed with the patient in a way that would satisfy either the professional or the patient disclosure standard.
- Delegation failures: The physician ultimately responsible for the treatment plan was not meaningfully involved in reviewing laboratory results or adjusting therapy, leaving those responsibilities to non-physician staff without adequate oversight.
Ethical guidance on informed consent has been explicit that a physician cannot delegate away the duty of securing that consent. A clinic structured around minimal physician involvement is building risk into its own operating model.
A men’s health clinic negligence expert witness is typically brought into a case precisely because one or more of these patterns appears in the medical record, and the expert’s role becomes explaining to a judge or jury why the gap between what happened and what the guidelines require actually matters to the patient’s outcome.
Can the standard of care hold in clinics across multiple locations?
How a single hormone optimization brand performs across several clinic locations rather than looking at one location in isolation comes as one of the most instructive pieces of evidence in this field. When a company operates multiple sites under one name, one set of marketing claims, and one clinical protocol on paper, the actual quality of care at each site often turns out to depend heavily on local staffing and on how strictly that individual location follows the written protocol.
In litigation, this matters because a plaintiff’s attorney will often look beyond the single clinic where their client was treated and ask whether the broader chain shows a pattern. If lab monitoring lapses, consent documentation gaps, and dosing inconsistencies appear at more than one location under the same ownership, that pattern can support an argument that the deficiency is not an isolated staff issue, because it is shown as a systemic operational choice, which changes both the legal theory available to the plaintiff and the damages exposure facing the defendant. What I have found is that when a multi-location operator can demonstrate consistent practices across every site, it can be powerful evidence that the standard of care was built into the business and not left to chance.
Conclusion
The legal exposure surrounding hormone optimization ultimately comes down to how a clinic operates when treatment becomes routine. A defensible program requires more than having qualified providers or following a written protocol; it requires a system that can withstand scrutiny when a patient’s outcome is challenged and the medical record becomes the primary evidence of what the clinic actually did. For attorneys, that makes the quality and consistency of the clinical record especially important, and for clinic operators, it makes clinical oversight part of risk management rather than an afterthought.
Frequently asked questions
- What makes hormone optimization clinics a growing target for malpractice litigation? Rapid market growth, combined with telehealth delivery and inconsistent adherence to established monitoring guidelines, increases both the number of patients treated and the risk of preventable errors.
- Can a clinic be liable even if the decision to prescribe testosterone was medically reasonable? A separate informed consent claim can proceed even when the underlying prescribing decision was defensible, if the patient was not properly told about the material risks.
- What should an attorney look for first when evaluating a potential testosterone replacement therapy (TRT) negligence case? The baseline lab work, the timing of follow-up monitoring, and the informed consent documentation, compared directly against the treatment guideline.
Jair Matis is a wellness and recovery expert witness.

